Janus Henderson Group PLC Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Janus Henderson Group PLC decreased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 96.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,319 shares of the company's stock after selling 675,069 shares during the quarter. Janus Henderson Group PLC owned approximately 0.05% of Pacira BioSciences worth $351,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Centiva Capital LP purchased a new stake in Pacira BioSciences during the 3rd quarter worth about $398,000. PDT Partners LLC purchased a new stake in Pacira BioSciences during the 3rd quarter worth about $3,469,000. Verition Fund Management LLC purchased a new stake in Pacira BioSciences during the 3rd quarter worth about $493,000. FORA Capital LLC purchased a new stake in Pacira BioSciences during the 3rd quarter worth about $431,000. Finally, BNP Paribas Financial Markets lifted its holdings in Pacira BioSciences by 269.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock worth $5,955,000 after purchasing an additional 288,662 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Trading Up 0.1 %

Shares of Pacira BioSciences stock traded up $0.01 during midday trading on Monday, reaching $19.87. 702,910 shares of the company's stock traded hands, compared to its average volume of 851,390. The company has a market cap of $917.40 million, a PE ratio of -9.78 and a beta of 0.80. The stock has a 50 day moving average of $17.27 and a 200-day moving average of $18.97. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 12th. Jefferies Financial Group raised their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Royal Bank of Canada raised their price objective on Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a report on Thursday, November 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.